大脑特异性microRNAs与阿尔茨海默病之间的相互作用
Nathan Tinu1, Bhupender Sharma1, Daniela Rodarte1
1Center of Emphasis in Neuroscience, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, TX, USA.
Neural regeneration research
|July 6, 2025
概括
脑特异性微RNAs (miRs) 的失调有助于阿尔茨海默病的进展. 这些miRs是神经元功能中的关键参与者,并可能作为阿尔茨海默病诊断的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是记忆丧失和大脑蛋白质聚合物.
- 阿尔茨海默病的确切原因仍在研究中,但microRNAs (miRs) 与其发展有关.
- 特定于大脑的miRs对于中枢神经系统功能和神经元发育至关重要.
研究的目的:
- 审查关键的大脑特异性微RNA (miRs) 参与阿尔茨海默氏症 (AD) 病原发生.
- 探索这些miRs在AD中的局部化,失调和功能作用.
- 突出miRs作为AD诊断和进展监测的生物标志物的潜力.
主要方法:
- 在阿尔茨海默病 (AD) 中对脑特异性微RNA (miRs) 的研究的文献综述.
- 鉴定和分析涉及AD病变发生的miRs.
- 检查miR在AD相关的细胞过程中的作用.
主要成果:
- 在阿尔茨海默氏病 (AD) 中,包括miR-9,miR-124和miR-146a在内的几种特定于大脑的microRNAs (miRs) 失调.
- 这些miRs位于大脑中,并影响关键的细胞过程,如自,陶酸化和神经炎症.
- 失调的miRs调节参与AD病理的基因,影响粉样β生产和细胞循环调节.
结论:
- 特定于大脑的microRNAs (miRs) 在阿尔茨海默病 (AD) 发病过程中发挥着重要作用.
- 这些miRs的失调会影响至关重要的细胞功能,导致疾病的进展.
- 作为早期诊断和阿尔茨海默病监测的潜在生物标志物,miR表达水平显示出希望.
更多相关视频
07:55Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
521
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
相关概念视频
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
01:26Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K